Some of the most exciting developments in the last fifty years have been in the biotechnology industry – which has also meant the emergence of some of the best investments for 2013.
Just look at the progress biotech has made in medicine.
Using advanced technology and research, scientists in the life sciences industry are working on cures for diseases that have plagued mankind for decades. In a relatively short period of time, biotechnology has produced medications that have pushed many forms of cancer to the brink of defeat. HIV infection went from a death sentence to a manageable – and almost cured – condition, in just a few decades.
Biotech share prices have reflected these successes.
And early investors in biotech have seen astronomical gains over the past four to five years.
Regeneron Pharmaceuticals Inc. (Nasdaq: REGN) has soared from less than $5 a share back in 2005 to more than $240 a share today as its drugs have been used to battle ophthalmological disease and several forms of cancer. Incyte Corp. (Nasdaq: INCY) has seen its stock price rise from $2 a share just four years ago to more than $20 today. Early investors in industry leader Amgen Inc. (Nasdaq: AMGN) have seen gains of almost 100 times their initial investment.
But those gains are far from over.
In fact, right now just may be the best time in history to be an investor in the biotechnology sector.
Why Biotech is Among the Best Investments of 2013
As the population ages the demand for new drugs and treatment is growing rapidly.
In response to this, the U.S. Food and Drug Administration has taken steps to speed up the testing and approval process for new drugs. Last year the agency approved 30% more new drugs than the year before – the most in 16 years.